Autres langues Perspective Therapeutics, Inc.

Actions

CATX

US46489V3024

Recherche biotechnologique et médicale

Marché Fermé - NYSE Autres places de cotation 22:00:00 28/07/2026			Varia. 5j.	Varia. 1 janv.
2,870 ^USD	+1,77 %		-1,71 %	+4,36 %

28/07	La thérapie de Perspective Therapeutics contre les tumeurs neuroendocrines reçoit la désignation de médicament orphelin dans l'UE	MT
17/07	Perspective Therapeutics : les données sur le [212Pb]VMT-α-NET acceptées pour une présentation orale au congrès de l'ESMO 2026	CI

Autres langues

28/07	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation
28/07	Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
17/07	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026
17/07	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026
08/07	Perspective Therapeutics, Inc. Announces Executive Changes
08/07	Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role
08/07	Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor
03/06	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort
03/06	Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
03/06	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study
21/05	Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
18/05	Perspective Therapeutics, Inc. Announces First Patients Dosed In New Cohorts Of Ongoing Phase 1/2a Studies
18/05	Perspective Therapeutics Doses First Patients for New Cohorts of Two Phase 1/2a Studies in Tumors
18/05	Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
11/05	Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
11/05	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
24/04	Perspective Therapeutics to Provide Several Upcoming Corporate Updates
20/04	Perspective Therapeutics Provides Updated Interim Results From Phase 1/2a Cancer Trial
20/04	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
20/04	Perspective Therapeutics Inc Presents Updated Interim Data of [212Pb]VMT-a-NET in Ongoing Phase 1/2A Clinical Trial
02/04	Perspective Therapeutics to Participate in Upcoming Investor Conferences
23/03	Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index
17/03	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
16/03	Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
16/03	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results